Loading organizations...
Zumutor Biologics is an immuno-oncology company focused on targeted natural killer (NK) cell therapeutics. It develops first-in-class therapeutic antibodies using its proprietary INABLR® Human Antibody platform. This platform creates high-diversity libraries to modulate innate immunity and the tumor microenvironment. Their lead asset, ZM008, is a human IgG1 monoclonal antibody targeting LLT1, enhancing NK cell cytotoxicity.
The company was founded in 2013 in Bangalore, India, based on the insight that innovative immunotherapies could effectively regulate the tumor microenvironment. Kavitha Iyer Rodrigues leads as Chief Executive Officer. Dr. Maloy Ghosh, Chief Scientific Officer, and Anirban Bhattacharya, Chief Financial Officer, comprise its leadership.
Zumutor Biologics’ therapies target advanced solid tumor patients; ZM008 is in clinical trials. The company’s vision is to advance therapeutic research by delivering next-generation immunotherapies. It aims to improve patient health through superior biologics, driven by a science-based approach.
Zumutor Biologics has raised $10.2M across 2 funding rounds.
Zumutor Biologics has raised $10.2M in total across 2 funding rounds.
Zumutor Biologics is a clinical-stage immuno-oncology company developing novel monoclonal antibodies targeting NK cells and the tumor microenvironment to treat solid tumors and lymphomas.[1][2][3] Its lead product, ZM008, is a first-in-class antibody against CLEC2D that received FDA IND clearance in 2023 and entered Phase 1 trials for head and neck squamous cell carcinoma, with manufacturing support from Catalent.[5][6] The company serves cancer patients by addressing unmet needs in innate immunity modulation through glyco-engineered antibodies, with additional pipeline candidates like ZM012 (preclinical lymphoma) and services for antibody discovery partnerships; it has raised ~$21.7M total funding and employs 50-200 people across US and India sites.[2][3][5]
Growth momentum includes GLP tox completion, 250L-scale manufacturing, Pre-IND submission, and promising ex-vivo data showing NK activation and tumor infiltration in xenograft models by 2022, alongside global patents and collaborations.[3]
Zumutor Biologics originated in 2013 in Bangalore, India, with $6M seed funding from Accel Partners, Aarin Capital, IDG Ventures, and KITVEN to build antibody platforms.[1][3] Founders leveraged expertise in antibody engineering and immuno-oncology, developing glyco-engineering, naïve/synthetic display libraries, and early assets like a trastuzumab biosimilar and Exendin-4 by 2014-2015.[3]
In 2015, the company incorporated in the US (initially Cambridge, MA; later Woburn, MA) and raised a $6M Series A from existing investors, filing global patents and expanding to immuno-oncology focus.[1][3] Key milestones include a 2021-2022 round raising $6.2M from Accel, Siana Capital, and Barath Innovation Fund, enabling preclinical advancement of leads like ZM008, plus global licensing of a breast cancer biologic and US/Europe partnerships.[3]
Zumutor rides the NK cell and innate immunity wave in immuno-oncology, shifting from T-cell focus (e.g., checkpoint inhibitors) toward tumor microenvironment modulation amid rising solid tumor resistance.[1][2][6] Timing aligns with post-2020 IO market growth, FDA's fast-track nods for NK therapies, and bispecific/CAR-NK demand, bolstered by their 2023 IND clearance amid ~$100B+ global IO spend.[5]
Market forces favor them: aging populations driving cancer incidence, biotech funding rebound for platforms, and India-US R&D hubs cutting costs. They influence the ecosystem via services accelerating partner pipelines and licensing (e.g., breast cancer biologic), fostering IO innovation in underserved areas like head/neck cancers.[3][5]
Zumutor's Phase 1 ZM008 data readouts (ongoing from 2024 start) could catalyze partnerships or further funding, with combo potential in solid tumors leveraging NK synergies.[5][6] Trends like AI-optimized antibodies and next-gen NK engagers will shape them, potentially expanding to autoimmune via innate immunity platforms.[2]
Their influence may grow through scale-up (post-250L manufacturing) and global deals, solidifying as a bridge between discovery services and proprietary IO assets—echoing their genesis in platform innovation for better biologics.[1][3]
Zumutor Biologics has raised $10.2M in total across 2 funding rounds.
Zumutor Biologics's investors include Accel, Bharat Innovation Fund, Siana Capital.
Zumutor Biologics has raised $10.2M across 2 funding rounds. Most recently, it raised $6.2M Series A in December 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 11, 2021 | $6.2M Series A | Accel, Bharat Innovation Fund, Siana Capital | — | Announced |
| Nov 1, 2019 | $4M Series A | Bharat Innovation Fund, Accel | — | Announced |